Morphogen-IX Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 1

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Morphogen-IX General Information

Description

Developer of bone morphogenetic protein receptors designed to offer treatment for pulmonary arterial hypertension. The company's receptors offer therapies that alleviate the symptoms of pulmonary arterial hypertension, enabling drug discovery professionals to ensure maximum capital efficiency without sacrificing quality.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Babraham Hall
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Babraham Hall
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Morphogen-IX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Feb-2021 Completed Generating Revenue
3. Early Stage VC (Series B) 18-Dec-2018 Completed Generating Revenue
2. Early Stage VC (Series A) 18-Jan-2016 $2.2M $2.2M Completed Startup
1. University Spin-Out 15-Jul-2015 Completed Startup
To view Morphogen-IX’s complete valuation and funding history, request access »

Morphogen-IX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Morphogen-IX’s complete cap table history, request access »

Morphogen-IX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of bone morphogenetic protein receptors designed to offer treatment for pulmonary arterial hypertension. The c
Drug Discovery
Cambridge, United Kingdom
1 As of 2022

San Diego, CA
 

Vienna, Austria
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Morphogen-IX Competitors (61)

One of Morphogen-IX’s 61 competitors is Endeavor BioMedicines, a Venture Capital-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Endeavor BioMedicines Venture Capital-Backed San Diego, CA
Apeptico Formerly VC-backed Vienna, Austria
Aurum Biosciences Venture Capital-Backed Glasgow, United Kingdom
PepGen Formerly VC-backed Boston, MA
Rein Therapeutics Formerly VC-backed Austin, TX
You’re viewing 5 of 61 competitors. Get the full list »

Morphogen-IX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Morphogen-IX Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cambridge Enterprise Ventures Venture Capital Minority
Cambridge Innovation Capital Venture Capital Minority
Index Ventures Venture Capital Minority
Medicxi Ventures (UK) Venture Capital Minority
To view Morphogen-IX’s complete investors history, request access »

Morphogen-IX FAQs

  • When was Morphogen-IX founded?

    Morphogen-IX was founded in 2015.

  • Where is Morphogen-IX headquartered?

    Morphogen-IX is headquartered in Cambridge, United Kingdom.

  • What is the size of Morphogen-IX?

    Morphogen-IX has 1 total employees.

  • What industry is Morphogen-IX in?

    Morphogen-IX’s primary industry is Drug Discovery.

  • Is Morphogen-IX a private or public company?

    Morphogen-IX is a Private company.

  • What is Morphogen-IX’s current revenue?

    The current revenue for Morphogen-IX is .

  • How much funding has Morphogen-IX raised over time?

    Morphogen-IX has raised $25.6M.

  • Who are Morphogen-IX’s investors?

    Cambridge Enterprise Ventures, Cambridge Innovation Capital, Index Ventures, and Medicxi Ventures (UK) have invested in Morphogen-IX.

  • Who are Morphogen-IX’s competitors?

    Endeavor BioMedicines, Apeptico, Aurum Biosciences, PepGen, and Rein Therapeutics are some of the 61 competitors of Morphogen-IX.

  • When was Morphogen-IX acquired?

    Morphogen-IX was acquired on 23-Feb-2021.

  • Who acquired Morphogen-IX?

    Morphogen-IX was acquired by Centessa Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process